Introduction: Vitamin D deficiency is emerging threat to patients with thalassemia. Adequate circulating levels of vitamin D are essential for optimal skeletal health and reducing fracture risk. The aim of this study was to evaluate the 25-OH-vitamin D levels in patients of thalassemia and compare its prevalence to healthy children. Methodology: In a case control study, 50 patients with beta thalassemia major (aged from 3 to 18 years) were compared with 50 sex and age matched children serves as a control group. Anthropometric measurement, Serum level of calcium, phosphorus, alkaline phosphatase, parathyroid hormone and 25-OH-vitamin D (25 hydroxycholecalciferol) were estimated for all patients & controls. Results: 25-OH-vitamin D deficiency was observed in 98% cases and 68% in control group. Difference in mean vitamin D levels between cases and controls was statistically significant (p<0.05). Weight and body mass index were significantly (p<0.05) lower in cases. Patient with beta thalassemia major compare to control had significantly (p<0.05) higher level of alkaline phosphatase and parathyroid hormone level. Conclusion: Thalassemia is associated with increased prevalence of 25-OH-vitamin D deficiency resulting in poor growth and quality of life in these children. This signifies the importance of therapeutic intervention.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.